Abstract is: Chronic allograft nephropathy (CAN) is a kidney disorder which is the leading cause of kidney transplant failure, occurring months to years after the transplant.
| disease | Q12136 |
| kidney disease | Q1054718 |
| transplant rejection | Q1765748 |
| P1995 | health specialty | urology | Q105650 |
| Q44913099 | A new alloantigen-independent control for chronic allograft nephropathy rat models. |
| Q33321328 | A non-parametric meta-analysis approach for combining independent microarray datasets: application using two microarray datasets pertaining to chronic allograft nephropathy |
| Q74015515 | A novel approach to the treatment of chronic allograft nephropathy |
| Q41256425 | A reproducible mouse model of chronic allograft nephropathy with vasculopathy. |
| Q84565081 | AGE formation blockade with aminoguanidine does not ameliorate chronic allograft nephropathy |
| Q46428216 | Adoptive transfer of primed CD4+ T-lymphocytes induces pattern of chronic allograft nephropathy in a nude rat model |
| Q62070385 | Aldosterone blockade in children with chronic allograft nephropathy |
| Q62619832 | Angiotensin Converting Enzyme Genotype and Chronic Allograft Nephropathy in Protocol Biopsies |
| Q79931107 | Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy |
| Q60196088 | Angiotensin-Converting Enzyme Gene Polymorphism in Chronic Allograft Nephropathy |
| Q44552323 | Apoptosis and treatment of chronic allograft nephropathy with everolimus |
| Q37293235 | Are the current chronic allograft nephropathy grading systems sufficient to predict renal allograft survival? |
| Q79285124 | Assessment of risk factors for chronic allograft nephropathy in renal transplant patients |
| Q45958515 | Association between Toll-like receptors 4 and 2 gene polymorphisms with chronic allograft nephropathy in Turkish children. |
| Q81210269 | Association between the presence of anti-HLA antibodies with acute rejection and chronic allograft nephropathy in the first year after kidney transplantation |
| Q46369075 | Association of C-509T and T869C polymorphisms of transforming growth factor-beta1 gene with chronic allograft nephropathy and graft survival in Korean renal transplant recipients |
| Q84004264 | Association of HHV-6 and HHV-7 reactivation with the development of chronic allograft nephropathy |
| Q46935358 | Association of cytokine polymorphisms with subclinical progressive chronic allograft nephropathy in Japanese renal transplant recipients: preliminary study |
| Q79921621 | Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') |
| Q38223778 | Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathy |
| Q33480997 | Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood |
| Q80000784 | Bone metaplasia associated with chronic allograft nephropathy |
| Q46310957 | C4d deposition is associated with chronic allograft nephropathy in rats and could be influenced by immunosuppressants |
| Q46539083 | C4d peritubular capillary staining in chronic allograft nephropathy and transplant glomerulopathy: an uncommon finding |
| Q46174193 | CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients |
| Q36908763 | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol |
| Q47309233 | Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial |
| Q82207410 | Chronic allograft nephropathy (CAN) in early renal protocol biopsies: does treatment of borderline and subclinical acute rejections prevent development and progression of CAN? |
| Q46678942 | Chronic allograft nephropathy and mycophenolate mofetil introduction in paediatric renal recipients |
| Q46475802 | Chronic allograft nephropathy and nephrotic range proteinuria |
| Q73668793 | Chronic allograft nephropathy categorised in chronic interstitial and vascular rejection |
| Q80355833 | Chronic allograft nephropathy in athymic nude rats after adoptive transfer of primed T lymphocytes |
| Q36582300 | Chronic allograft nephropathy in paediatric renal transplantation |
| Q46139592 | Chronic allograft nephropathy in rats is improved by the intervention of rhein |
| Q57703972 | Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism |
| Q44419237 | Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy |
| Q38195716 | Chronic allograft nephropathy or interstitial fibrosis and tubular atrophy: what is in a name? |
| Q34236920 | Chronic allograft nephropathy score before sirolimus rescue predicts allograft function in renal transplant patients |
| Q44460453 | Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts |
| Q33723791 | Chronic allograft nephropathy: An update |
| Q43620709 | Chronic allograft nephropathy: a prospective randomised trial of cyclosporin reduction with or without mycophenolate mofetil |
| Q35757120 | Chronic allograft nephropathy: causes of death and mortality risk factors-a review of the last decade in Spain |
| Q34501818 | Chronic allograft nephropathy: current concepts and future directions |
| Q74617351 | Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease |
| Q81344829 | Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma |
| Q83314660 | Chronic allograft nephropathy: intraepithelial signals generated by transforming growth factor-beta and bone morphogenetic protein-7 |
| Q35841352 | Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication |
| Q43620732 | Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution |
| Q77908791 | Chronic allograft nephropathy: the inevitable outcome of renal transplantation? |
| Q77369885 | Chronic allograft nephropathy: what can the biopsy tell us? |
| Q37133957 | Chronic allograft nephropathy: what have we learned from protocol biopsies? |
| Q61817154 | Cigarette smoking and chronic allograft nephropathy |
| Q83808700 | Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients |
| Q42169403 | Clinical experience of mycophenolate mofetil in the treatment of chronic allograft nephropathy in kidney transplantation: three-year follow-up |
| Q78656042 | Clinical relevance of immunohistochemical staining for ecto-AMPase and ecto-ATPase in chronic allograft nephropathy (CAN) |
| Q43796022 | Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone |
| Q83377108 | Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy |
| Q46856408 | Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks |
| Q43237438 | Conversion from cyclosporin A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model |
| Q34221329 | Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy |
| Q80502269 | Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy |
| Q94486030 | Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy |
| Q43274507 | Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion |
| Q46966013 | Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients |
| Q44131474 | Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up |
| Q54769556 | Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. |
| Q43416695 | Cytomegalovirus accelerates chronic allograft nephropathy in a rat renal transplant model with associated provocative chemokine profiles |
| Q81774729 | Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats |
| Q87339022 | Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin |
| Q81778125 | Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy |
| Q53964234 | Detection of chronic allograft nephropathy by quantitative doppler imaging. |
| Q51036331 | Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. |
| Q82547242 | Differential expression of profibrotic and growth factors in chronic allograft nephropathy |
| Q79854817 | Distribution of donor-specific antibodies in the cortex and the medulla of renal transplants with chronic allograft nephropathy |
| Q80808560 | Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy |
| Q36690177 | Dramatic early event in chronic allograft nephropathy: increased but not decreased expression of MMP-9 gene |
| Q56765660 | Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy |
| Q45248056 | Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. |
| Q46442922 | Early conversion from cyclosporine to tacrolimus increases renal graft function in chronic allograft nephropathy at BANFF stages I and II. |
| Q35757117 | Early diagnosis of chronic allograft nephropathy by means of protocol biopsies |
| Q83341190 | Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy |
| Q79438883 | Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation |
| Q39097123 | Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats |
| Q80094251 | Early-morning urine osmolality in patients with chronic allograft nephropathy |
| Q95380121 | Effect analysis of 1-year posttransplant body mass index on chronic allograft nephropathy in renal recipients |
| Q83448562 | Effect of Cordyceps sinensis on renal function of patients with chronic allograft nephropathy |
| Q46843849 | Effect of ligustrazine on chronic allograft nephropathy in rats |
| Q79820476 | Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients |
| Q46310948 | Effects of mycophenolate mofetil on chronic allograft nephropathy by affecting RHO/ROCK signal pathways |
| Q45200668 | Effects of progesterone and selective oestrogen receptor modulators on chronic allograft nephropathy in rats |
| Q46832116 | Efficacy of Hushen Gujing (HSGJ) in preventing chronic allograft nephropathy in rats |
| Q80102224 | Endothelin-mediated oncofetal fibronectin expression in chronic allograft nephropathy |
| Q44927347 | Establishing the molecular pathways involved in chronic allograft nephropathy for testing new noninvasive diagnostic markers |
| Q80374101 | Evaluating the accuracy of functional biomarkers for detecting histological changes in chronic allograft nephropathy |
| Q84757264 | Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy |
| Q26864535 | Experimental rat models of chronic allograft nephropathy: a review |
| Q46839584 | Explorative study on mechanism and drug intervention for chronic allograft nephropathy induced by renal ischemia-reperfusion injury |
| Q46629548 | Expression of matrix metalloproteinase-9 in renal tissues of rats with chronic allograft nephropathy at early stage and the role thereof |
| Q35643599 | Five-year follow-up after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft nephropathy |
| Q59491290 | GENE THERAPY WITH HEPATOCYTE GROWTH FACTOR ATTENUATES THE PROGRESSION OF CHRONIC ALLOGRAFT NEPHROPATHY |
| Q43963147 | Glomerular hyperfiltration, intrarenal hemodynamics, and chronic allograft nephropathy: physiopathology of chronic allograft nephropathy |
| Q44549975 | Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy |
| Q77369872 | Graft endothelium and chronic allograft nephropathy: insight from in vitro trans-differentiation of smooth muscle cells induced by mismatched lymphocytes |
| Q34639571 | HA-1 mismatch has significant effect in chronic allograft nephropathy in clinical renal transplantation |
| Q46562290 | Heat shock protein 27 in chronic allograft nephropathy: a local stress response |
| Q73928025 | Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats |
| Q57582463 | High CXCL10 Expression in Rejected Kidneys and Predictive Role of Pretransplant Serum CXCL10 for Acute Rejection And Chronic Allograft Nephropathy |
| Q74725312 | Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients |
| Q35757123 | Histological features with clinical impact in chronic allograft nephropathy: review of 66 cases |
| Q43675929 | Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients |
| Q45248048 | Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients |
| Q81964900 | Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy |
| Q33959646 | Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods |
| Q73012935 | Immunohistochemical analysis of tubulointerstitial changes of chronic allograft nephropathy |
| Q81258061 | Immunosuppression in renal transplantation: viral diseases and chronic allograft nephropathy |
| Q45021815 | Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation |
| Q84569050 | Impact of recurrent disease and chronic allograft nephropathy on the long-term allograft outcome in patients with IgA nephropathy |
| Q81418070 | Improved long-term graft function in pediatric transplant renal recipients with chronic allograft nephropathy |
| Q54310171 | Increased Expression of p-Akt correlates with Chronic Allograft Nephropathy in a Rat Kidney Model. |
| Q58821447 | Increased dietary salt accelerates chronic allograft nephropathy in rats |
| Q73143481 | Increased expression of P21((WAF1/CIP1)) CDKI gene in chronic allograft nephropathy correlating with the number of acute rejection episodes |
| Q73456495 | Increased expression of p16(INK4a) and p27(Kip1) cyclin-dependent kinase inhibitor genes in aging human kidney and chronic allograft nephropathy |
| Q73328497 | Increased expression of p21 (WAF1/CIP1) cyclin-dependent kinase (CDK) inhibitor gene in chronic allograft nephropathy correlates with the number of acute rejection episodes |
| Q57975233 | Inducible nitric oxide synthase expression in vascular and glomerular structures of human chronic allograft nephropathy |
| Q28175580 | Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation |
| Q46399145 | Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats |
| Q81174772 | Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy |
| Q81543151 | Interstitial expression of heat-shock protein 47 correlates with capillary deposition of complement split product C4d in chronic allograft nephropathy |
| Q71324547 | Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy |
| Q78293948 | Intragraft messenger RNA expression of angiotensinogen: relationship with transforming growth factor beta-1 and chronic allograft nephropathy in kidney transplant patients |
| Q81308335 | Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy |
| Q37107014 | Involvement of indirectly allostimulated CD4+CD43highCD45RO+ T cell proliferation in the development of chronic allograft nephropathy |
| Q42169354 | Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? |
| Q82224088 | Limitations of targeting rate-limiting step of renin-angiotensin-aldosterone system in experimental chronic allograft nephropathy |
| Q82888074 | Lipid profile in chronic allograft nephropathy |
| Q35078258 | Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis in chronic allograft nephropathy |
| Q46419515 | Long-term graft outcome in patients with chronic allograft nephropathy after immunosuppression modifications. |
| Q46841620 | Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations |
| Q78083687 | Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy |
| Q60603239 | Loss of Direct and Maintenance of Indirect Alloresponses in Renal Allograft Recipients: Implications for the Pathogenesis of Chronic Allograft Nephropathy |
| Q81680483 | Loss of peritubular capillaries in the development of chronic allograft nephropathy |
| Q37264359 | Low-dose carbon monoxide inhibits progressive chronic allograft nephropathy and restores renal allograft function. |
| Q42637895 | Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil |
| Q83096403 | Management of chronic allograft nephropathy |
| Q37429331 | Management of chronic allograft nephropathy: a systematic review |
| Q43640095 | Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation |
| Q84456236 | Microarray gene expression profiling of chronic allograft nephropathy in the rat kidney transplant model |
| Q44148838 | Mig, IP-10, and CXCR3 gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil |
| Q34322260 | Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy |
| Q23910159 | Nephron number determines susceptibility to renal mass reduction-induced CKD in Lewis and Fisher 344 rats: implications for development of experimentally induced chronic allograft nephropathy |
| Q34659447 | Oral hydrogen water prevents chronic allograft nephropathy in rats |
| Q43685018 | Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss? |
| Q35997416 | Oxidative stress and chronic allograft nephropathy |
| Q35175076 | Pathogenesis and molecular mechanisms of chronic allograft nephropathy |
| Q77722625 | Pathogenesis of chronic allograft nephropathy |
| Q74650743 | Pathologic classification of chronic allograft nephropathy: pathogenic and prognostic implications |
| Q88177136 | Peripheral Blood Regulatory T Cells Are Diminished in Kidney Transplant Patients With Chronic Allograft Nephropathy |
| Q81847907 | Peritubular capillaritis in early renal allograft is associated with the development of chronic rejection and chronic allograft nephropathy |
| Q35137493 | Pharmacotherapeutic approach to prevent or treat chronic allograft nephropathy |
| Q46650136 | Polymorphism of the methylenetetrahydrofolate reductase C677T gene with chronic allograft nephropathy in renal transplant recipients |
| Q80935745 | Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy |
| Q33246671 | Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens |
| Q44871076 | Predicting the grade of Banff 97 classification of chronic allograft nephropathy based on examination of graft dysfunction (a preliminary report). |
| Q43037627 | Prediction of chronic allograft nephropathy using classification trees |
| Q51981967 | Predictors of chronic allograft nephropathy from protocol biopsies using histological and immunohistochemical techniques. |
| Q44647492 | Pretransplant and early posttransplant predictors of chronic allograft nephropathy in cadaveric kidney allograft--a single-center analysis of 1112 cases |
| Q81600333 | Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events |
| Q78016254 | Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study |
| Q37723175 | Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program |
| Q46702673 | Prevention of chronic allograft nephropathy with vitamin D. |
| Q77090324 | Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis |
| Q46511489 | Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats. |
| Q45028960 | Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration |
| Q80605792 | Protective effects of atorvastatin on chronic allograft nephropathy in rats |
| Q80502276 | Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy |
| Q77959222 | Protocol biopsies and risk factors associated with chronic allograft nephropathy |
| Q79124598 | Protocol biopsies as predictors of chronic allograft nephropathy |
| Q44997891 | Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long-term renal-graft survival |
| Q39749152 | Quantitative digital histochemistry with methenamine silver staining in renal allograft biopsies excluding pure chronic allograft nephropathy cases. |
| Q46763752 | Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients |
| Q64452896 | Re: the association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation |
| Q73818114 | Re: the association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation |
| Q77369861 | Recipient age affects chronic allograft nephropathy in rats |
| Q42690733 | Recipient age and risk of chronic allograft nephropathy in primary deceased donor kidney transplant |
| Q79829189 | Reduction in chronic allograft nephropathy by inhibition of p38 mitogen-activated protein kinase |
| Q46492805 | Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling |
| Q86406125 | Reduction of osteopontin in vivo inhibits tubular epithelial to mesenchymal transition in rats with chronic allograft nephropathy |
| Q78693305 | Relative contribution of HLA disparity to chronic allograft nephropathy |
| Q43889585 | Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies |
| Q46974285 | Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats |
| Q46632322 | Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome |
| Q50847726 | Rethinking chronic allograft nephropathy: the concept of accelerated senescence. |
| Q80154369 | Retraction: Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy |
| Q45195098 | Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study |
| Q45248050 | Role of apolipoprotein E epsilon 4 allele on chronic allograft nephropathy after renal transplantation. |
| Q34259063 | Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy |
| Q46511495 | SDF-1 plays a key role in chronic allograft nephropathy in rats |
| Q64089155 | SDF‑1/CXCR4 induces epithelial‑mesenchymal transition through activation of the Wnt/β‑catenin signaling pathway in rat chronic allograft nephropathy |
| Q85748800 | Safety and efficacy of everolimus in chronic allograft nephropathy |
| Q79285130 | Significance of peritubular capillary basement membrane multilamellation in diagnosis of chronic allograft nephropathy |
| Q73254018 | Significance of tubulitis in chronic allograft nephropathy: a clinicopathologic study |
| Q79348898 | Sirolimus attenuates chronic allograft nephropathy in an experimental rat kidney transplantation model |
| Q79438969 | Sirolimus attenuates the rate of progression of early chronic allograft nephropathy |
| Q46970910 | Sirolimus in chronic allograft nephropathy in pediatric recipients |
| Q80149969 | Sirolimus is not always responsible for new-onset proteinuria after conversion for chronic allograft nephropathy |
| Q83150702 | Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial |
| Q35841386 | Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors |
| Q62619830 | Subclinical Rejection Associated with Chronic Allograft Nephropathy in Protocol Biopsies as a Risk Factor for Late Graft Loss |
| Q81603752 | Surgical transplant physical examination: correlation of renal resistance index and biopsy-proven chronic allograft nephropathy |
| Q34161119 | Surrogate markers of chronic allograft nephropathy |
| Q44468261 | TGF-beta1 expression and chronic allograft nephropathy in protocol kidney graft biopsy |
| Q58376368 | TGF-beta1 in chronic allograft nephropathy following renal transplantation |
| Q30396112 | TSI ultrasound elastography for the diagnosis of chronic allograft nephropathy in kidney transplanted patients |
| Q44157262 | The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation |
| Q82818030 | The contribution of podocytes to chronic allograft nephropathy |
| Q53789141 | The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. |
| Q54580816 | The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways. |
| Q43928123 | The impact of ICAM1 and VCAM1 gene polymorphisms on chronic allograft nephropathy and transplanted kidney function |
| Q95798106 | The natural history of chronic allograft nephropathy |
| Q35746823 | The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging |
| Q89949573 | The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy |
| Q81379235 | The role of cytomegalovirus infection in chronic allograft nephropathy |
| Q53579926 | The role of renin-angiotensin system in the chronic allograft nephropathy: an immunohistochemical study. |
| Q50078042 | The roles of IL-17 and CXCR4 in chronic allograft nephropathy in rat models |
| Q81327739 | The significance of Tc-99m DTPA renal scintigraphy for the demonstration of progressive functional changes that accompany chronic allograft nephropathy |
| Q84201879 | Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats |
| Q46833394 | Therapeutic effect of sirolimus against chronic allograft nephropathy in kidney transplant recipients |
| Q46399698 | Therapy strategies in the prevention of chronic allograft nephropathy |
| Q54778490 | Toll-like receptors-related genes in kidney transplant patients with chronic allograft nephropathy and acute rejection. |
| Q88156988 | Transient elastography: a new noninvasive diagnostic tool for assessment of chronic allograft nephropathy |
| Q46187799 | Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine |
| Q46208830 | Treatment of chronic allograft nephropathy with combination of enalapril and bailing capsule |
| Q43963143 | Treatment of chronic allograft nephropathy with mycophenolate mofetil after kidney transplantation: a Spanish multicenter study |
| Q46452909 | Tubular and glomerular proteinuria in diagnosing chronic allograft nephropathy with relevance to the degree of urinary albumin excretion. |
| Q77621287 | Type 2 angiotensin II receptor expression in human renal allografts: an association with chronic allograft nephropathy |
| Q81835776 | Ultrastructural analysis of the Fisher to Lewis rat model of chronic allograft nephropathy |
| Q28250891 | Upregulation of ADAM19 in chronic allograft nephropathy |
| Q43874841 | Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial |
| Q42845904 | Urinary connective tissue growth factor as a biomarker chronic allograft nephropathy in a rat model |
| Q33764407 | Urinary proteomic analysis of chronic allograft nephropathy |
| Q73887223 | Urine excretion of transforming growth factor-beta1 in chronic allograft nephropathy |
| Q87252740 | Urine periostin as a biomarker of renal injury in chronic allograft nephropathy |
| Q48871861 | Vagal stimulation in brain dead donor rats decreases chronic allograft nephropathy in recipients |
| Q44260942 | Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: a case-control study |
| Q44976418 | Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss? |
| Q36326277 | What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations. |
| Q95559016 | [Acupuncture-moxibustion for chronic allograft nephropathy: a randomized controlled trial] |
| Q91863992 | [Application of intravoxel incoherent motion diffusion weighted imaging for assessment of early chronic allograft nephropathy] |
| Q80421078 | [Association between transforming growth factor beta-1 gene polymorphism and chronic allograft nephropathy] |
| Q84981297 | [Changes of peripheral blood CD4(+)CD25(+) regulatory T cells and TREG-related Foxp3 gene expression at the onset of chronic allograft nephropathy] |
| Q78746398 | [Chronic allograft nephropathy: its diagnosis and treatment] |
| Q81075479 | [Chronic rejection and chronic allograft nephropathy] |
| Q82884497 | [Clinical observation on treatment of chronic allograft nephropathy with bailing capsule] |
| Q95785314 | [Clinical observation on treatment of chronic allograft nephropathy with colquhounia root tablet combined with immunosuppressive protocol] |
| Q83445230 | [Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: a 4-year prospective study] |
| Q81752360 | [Expressions of transforming growth factor-beta1 and collagen IV in renal tissues of patients with chronic allograft nephropathy] |
| Q78746403 | [Immunological factors for chronic rejection and the methods for the prevention of chronic allograft nephropathy] |
| Q78746412 | [Non-immunological risk factors associated with chronic allograft nephropathy following kidney transplantation] |
| Q82743787 | [Prevention of chronic allograft nephropathy] |
| Q79163704 | [Role of transforming growth factor beta-1 gene polymorphisms in the development of chronic allograft nephropathy in renal transplant recipients] |
| Q50277257 | [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus]. |
| Q86001399 | [The overview of chronic allograft nephropathy treated by integrative medicine] |
| Q80957431 | [The significance of angiotensin converting enzyme inhibitors in therapy in chronic allograft nephropathy] |
| Category:Chronic allograft nephropathy | wikimedia | |
| Chronische Transplantatnephropathie | wikipedia | |
| Chronic allograft nephropathy | wikipedia | |
| Disfunzione cronica del trapianto renale | wikipedia |
Search more.